SCHEMBL3085322

SCHEMBL3085322

CC1(c2ccc(O)cc2)C(=O)Nc2c1ccc(F)c2F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 4/20 0.53
MMP9 P14780 3/20 0.53
HTR6 P50406 3/20 0.43
CNR1 P21554 3/20 0.40
GPR55 Q9Y2T6 3/20 0.40
HTT P42858 1/20 0.40
GPR35 Q9HC97 1/20 0.40
CHRM2 P08172 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
KCNH2 Q12809 1/20 0.35
POLB P06746 1/20 0.32
CASP6 P55212 1/20 0.32
AKR1B1 P15121 1/20 0.32
KDM4E B2RXH2 1/20 0.31
GAA P10253 1/20 0.31
GFER P55789 1/20 0.31
MMP13 P45452 2/20 0.31
MMP3 P08254 1/20 0.31
MMP8 P22894 1/20 0.31
PKM P14618 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29385169 0.82 GPR55 (0.56) MMP2MMP9HTR6CNR1GPR55
SCHEMBL3070533 0.82 GPR55 (0.56) MMP2MMP9HTR6CNR1GPR55
SCHEMBL5478134 0.81 POLB (0.41) MMP2MMP9HTR6CNR1GPR55
SCHEMBL3092349 0.79 CNR1 (0.38) MMP2MMP9HTR6CNR1GPR55
SCHEMBL3190942 0.79 CNR1 (0.57) MMP2MMP9HTR6CNR1GPR55
SCHEMBL3091137 0.79 CNR1 (0.38) MMP2MMP9HTR6CNR1GPR55
SCHEMBL3192059 0.78 CNR1 (0.52) MMP2MMP9CNR1GPR55HTT
SCHEMBL3084192 0.77 CNR1 (0.36) MMP2MMP9CNR1GPR55HTT
SCHEMBL3092453 0.76 CNR1 (0.50) MMP2MMP9HTR6CNR1GPR55
SCHEMBL3089397 0.76 CNR1 (0.35) MMP2MMP9CNR1GPR55HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100227863-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS TOPOTARGET A/S (DK) 2010-09-09 US claimed
EP-2139856-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE-COMPOUNDS Topotarget A/S (DK) 2010-01-06 EP claimed
WO-2008129075-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE-COMPOUNDS TOPOTARGET A/S (DK) 2008-10-30 WO claimed
US-20100227863-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS TOPOTARGET A/S (DK) 2010-09-09 US disclosed
US-20100227863-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS TOPOTARGET A/S (DK) 2010-09-09 US disclosed
US-20100227863-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS TOPOTARGET A/S (DK) 2010-09-09 US disclosed
WO-2008129075-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE-COMPOUNDS TOPOTARGET A/S (DK) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227863-A1 SUBSTITUTED 3-(4-HYDROXYPHENYL)-INDOLIN-2-ONE COMPOUNDS TPH2, TPH1, HTR2C MMP2 2138/4885MMP9 3892/4885HTR6 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.